Q32 Bio (STU:DB0) Short Interest


STU:DB0 Q32 Bio Inc STU:DB0
17 GF Score
Price €9.65
! 2 Warning Signs
View Full Analysis

What is Q32 Bio Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:DB0 vs ABOS, TNYA, MDWD: Short Interest Comparison

For the Biotechnology subindustry, Q32 Bio's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Short Interest distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Short Interest falls into.


STU:DB0
17GF Score
Q32 Bio Inc STU:DB0
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio Business Description

Other Exchanges QTTB:USADB0:Germany
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for STU:DB0

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.65
Price